ArticleEuropean journal of nuclear medicine and molecular imaging2018
The central zone has increased
Article in European journal of nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- PET/MRI in prostate cancer: a systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2021Pooled it
- The German Cancer Consortium (DKTK) multi-center prospective phase 1/2European journal of nuclear medicine and molecular imaging · 2026Trial
- Pathological and radiological features of false-positive lesions on [European journal of nuclear medicine and molecular imaging · 2025Article
- The impact of integrating PRIMARY score or SUVmax with MRI-based risk models for the detection of clinically significant prostate cancer.European journal of nuclear medicine and molecular imaging · 2025Article
- Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice.Experimental hematology & oncology · 2024Review
- A single-center, multi-factor, retrospective study to improve the diagnostic accuracy of primary prostate cancer using [European journal of nuclear medicine and molecular imaging · 2024Article
- Comparison of tracer kinetic models forEJNMMI research · 2024Article
- Comparison of Tracer Kinetic Models for 68Ga-PSMA-11 PET in Intermediate Risk Primary Prostate Cancer Patients.Research square · 2023Article
- The PRIMARY Score: Using IntraprostaticJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Development and validation ofEJNMMI research · 2022Article
- Article
- Diagnostic performance ofEuropean journal of nuclear medicine and molecular imaging · 2021Article
- Metal artifact reduction inEuropean journal of hybrid imaging · 2020Article
- Correlation of SUVMolecular imaging and radionuclide therapy · 2019Article
- Quantitative performance and optimal regularization parameter in block sequential regularized expectation maximization reconstructions in clinicalEJNMMI research · 2018Article
- Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine.American journal of nuclear medicine and molecular imaging · 2018Review
- Target Volume Optimization for Localized Prostate Cancer.Practical radiation oncologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeGiven the good correlation between PSMA expression and intraglandular tumour aggressiveness based on immunohistochemistry, there is increasing interest in
methodsWe retrospectively analysed all patients who underwent a staging
resultsOf 283 consecutive patients scanned with
conclusionOur results suggest that higher
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.